General

Ireland’s NCCP Issues New Guidance on Biosimilars in Oncology

By Hospital Professional News September 5, 2017 Updated February 4, 2022 3 min read

Ireland’s National Cancer Control Programme (NCCP) has issued new guidance on the use of biosimilar medicines in the treatment of cancer.

The guidance includes recommendations on 4 areas of concern with biosimilar products:

For verified healthcare professionals

Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.

Register for free Log in

Join the conversation Cancel reply

Comments are open to registered members. Log in or register to share your thoughts on this article.

Log in to comment Register for free